Florida’s AIDS Drug Assistance Program has long been a lifeline for low‑income people living with HIV, helping them afford the medications and insurance that keep the virus in check and prevent transmission. In early 2026, that lifeline abruptly tightened: the state moved to slash eligibility, drop a leading HIV drug from its formulary, and phase out premium assistance — prompting a high‑stakes legal challenge that asks whether agency officials can remake a critical public‑health program without going through Florida’s rulemaking process.
What Florida Changed
Florida runs an AIDS Drug Assistance Program (ADAP) that either supplies HIV medications directly or helps pay insurance premiums for low‑income residents living with HIV or AIDS. People could qualify with incomes up to 400% of the federal poverty level. In 2024, the program served more than 32,000 Floridians, about half of whom were between 138% and 400% of the poverty line.
All that changed with the notices the Florida Department of Health sent at the beginning of this year. Those letters said that starting March 1, the state would tighten income limits to 130% of the federal poverty level and end ADAP premium assistance. They also said the state would remove Biktarvy (a once‑daily, first‑line HIV regimen) from the formulary and limit Descovy (a newer drug with fewer kidney and bone side effects than its predecessor) to people with certain kidney conditions.
Last week, that went into place. Officials frame the move as a response to rising insurance premiums and a projected $120 million shortfall. Advocacy groups and national experts warn that more than 16,000 Floridians (roughly half of all ADAP clients) could lose coverage under the new rules.
Can Florida Rewrite ADAP by Memo?
Not long after, the Florida Department of Health was taken to court–well, to the state’s Division of Administrative Hearings, anyway. The Department is the body that decides who qualifies for ADAP and which drugs it will cover, and has been making those decisions through policy updates and formulary changes. The lawsuit was filed by AIDS Healthcare Foundation (AHF), a major HIV‑care nonprofit in the state, and an anonymous ADAP client.
They aren’t asking the judge to decide whether the cuts are good policy. Instead, they claim the Department should have used Florida’s formal rulemaking process, but instead rewrote who qualifies and what drugs are covered by sending letters, changing its website, and revising the formulary.
The plaintiffs allege that what the Department did here (lowering the income cutoff, ending premium assistance, and restricting access to drugs like Biktarvy and Descovy) all amount to putting out new rules in substance, even if the agency has not formally called them rules. They argue that Florida law requires such broad, binding policy changes to go through public notice‑and‑comment procedures, and they are asking the tribunal to bar the Department from relying on these new policies.
Why the Cuts Matter for People With HIV
Modern HIV treatment turns what was once a terminal illness into a chronic, manageable condition. But its success depends on uninterrupted access to antiretroviral medications, regular lab monitoring, and medical care. The complaint describes ADAP’s premium support as the primary way many Floridians living with HIV afford comprehensive insurance that covers not just HIV drugs but the full range of physical and mental health care they need.
The petitioners (along with outside clinicians and advocacy organizations) warn that restricting coverage, eliminating premium assistance, and forcing switches away from preferred regimens like Biktarvy and Descovy can lead to treatment interruptions, viral rebound, increased risk of drug resistance, hospitalizations, and preventable deaths. They also say these changes increase the risk of onward HIV transmission at the population level.
Policy Choice or Unlawful Shortcut?
At bottom, the case asks whether Florida can change who qualifies for ADAP and which drugs it covers through letters, website updates, and internal policy rather than through formal rulemaking.
The petitioners say these income cuts, the end of premium assistance, and the drug limits are “rules” in substance because they apply broadly and change people’s rights, so they must go through Florida’s notice‑and‑comment procedures. They’re asking the judge to declare the policies invalid as unpromulgated rules and to stop the Department from enforcing them.
State health officials have publicly defended the cuts as a difficult but necessary budget decision. The Department of Health points to rising health‑insurance premiums, flat federal Ryan White funding, and the need to “ensure resources [reach] the greatest number of individuals within our funding constraints,” arguing that limiting ADAP to those at or below 130% of the federal poverty level will prevent a large projected shortfall.
The state has emphasized that it will still provide HIV medications directly for the lowest‑income clients and has announced a short transition window for people who lose coverage to connect with other resources, such as manufacturer patient‑assistance programs, nonprofit co‑pay support, and community health centers. Critics say that the timeline is unrealistic in a fragmented insurance market and does little to prevent dangerous interruptions in treatment.
What Happens Next
Because the challenged changes were slated to take effect March 1, the petition asks for an expedited hearing and rapid decision timeline, arguing that thousands of Floridians could lose “life‑saving” benefits and face treatment interruptions if the cuts go forward unchecked. While the Department has since moved to formalize some of its policy through proposed and emergency rules, that shift does not erase the core dispute over whether its initial rollout complied with Florida administrative law.
If the legal fight seems removed from reality, at least for Floridians living with HIV, it’s about a lot more than how the government paperwork gets pushed. It will define how far Florida can cut ADAP to save money, and how secure people’s access to life‑saving HIV treatment really is.
Related Resources:
- A Guide to Recent Medicaid Changes (FindLaw’s Law and Daily Life)
- Legal Protections for People Living With HIV (FindLaw’s Learn About the Law)
- Discrimination Against HIV/AIDS Patients (FindLaw’s Learn About the Law)
